GlassScriptPhysician profile
Omer A Idrees
NPI 1437619939
$5,066.22
in general payments reported to CMS, 2019-2025
24 companies · $3,592 in 2025
The $3,592 reported for 2025 was more than what 81% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $125 · 2021: $107 · 2023: $123 · 2024: $1,120 · 2025: $3,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,834.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $812.80 | 2024-2025 | Krystexxa, Otezla, Uplizna |
| Astrazeneca Pharmaceuticals LP | $615.68 | 2020-2025 | Saphnelo |
| Ucb, INC. | $490.72 | 2024-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $451.91 | 2024-2025 | |
| Janssen Biotech, INC. | $396.08 | 2024-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $325.48 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $299.36 | 2025 | |
| Genzyme Corporation | $247.71 | 2024-2025 | |
| Glaxosmithkline, LLC. | $247.15 | 2024-2025 | Benlysta, Nucala |
| Ferring Pharmaceuticals INC. | $152.39 | 2025 | Euflexxa |
| Ani Pharmaceuticals, INC. | $126.72 | 2024-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $111.54 | 2024-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $95.11 | 2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $94.38 | 2024-2025 | Orencia |
| Dexcom, INC. | $93.48 | 2024 | Dexcom G6 Transmitter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $93.06 | 2024 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.15 | 2025 | Jascayd, Ofev |
| Sobi, INC | $67.12 | 2024-2025 | |
| Radius Health, INC. | $59.18 | 2025 | |
| Sandoz INC. | $56.40 | 2024-2025 | Hyrimoz, Jubbonti |
| Alexion Pharmaceuticals, INC. | $55.63 | 2025 | Strensiq |
| Genentech USA, INC. | $54.78 | 2024-2025 | Actemra |
| Kyowa Kirin, INC. | $27.00 | 2025 | |
| Invivyd INC | $19.39 | 2025 | Pemgarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omer Idrees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.